MSA Glial Pathology — Detailed Comparison with Parkinson's Disease

MSA Glial Pathology — Detailed Comparison with Parkinson's Disease

Multiple System Atrophy (MSA) fundamentally differs from Parkinson's Disease (PD) in its cellular target: while PD primarily affects [dopaminergic neurons](/cell-types/dopaminergic-neurons), MSA is characterized by oligodendrocyte dysfunction as the primary pathogenic event[@wenning2009] [wenning2009](https://doi.org/10.1002/ana.21535). This page provides a detailed comparison of glial pathology between MSA and PD, addressing key gaps in understanding the mechanistic divergence between these α-synucleinopathies.

Fundamental Difference: Target Cell Type

The most critical distinction between MSA and PD lies in which cell type harbors the pathological α-synuclein aggregates:

| Feature | MSA | PD |
|---------|-----|-----|
| Primary affected cell | Oligodendrocyte | Dopaminergic neuron |
| Inclusion type | Glial cytoplasmic inclusions (GCIs) | Lewy bodies |
| GCI:LB ratio | ~10:1 | N/A (neurons only) |
| Myelin involvement | Primary destruction | Secondary change |
| Clinical progression | More rapid | Relatively slower |

This oligodendrogliopathic character distinguishes MSA from all other neurodegenerative diseases[@jellinger2023] [jellinger2023](https://doi.org/10.1007/s00401-023-02567-4).

Pathogenesis Comparison

MSA: Primary Oligodendrogliopathy

In MSA, oligodendrocytes are the primary targets of α-synuclein pathology[@yamada2024]:

MSA Glial Pathology — Detailed Comparison with Parkinson's Disease

Multiple System Atrophy (MSA) fundamentally differs from Parkinson's Disease (PD) in its cellular target: while PD primarily affects [dopaminergic neurons](/cell-types/dopaminergic-neurons), MSA is characterized by oligodendrocyte dysfunction as the primary pathogenic event[@wenning2009] [wenning2009](https://doi.org/10.1002/ana.21535). This page provides a detailed comparison of glial pathology between MSA and PD, addressing key gaps in understanding the mechanistic divergence between these α-synucleinopathies.

Fundamental Difference: Target Cell Type

The most critical distinction between MSA and PD lies in which cell type harbors the pathological α-synuclein aggregates:

| Feature | MSA | PD |
|---------|-----|-----|
| Primary affected cell | Oligodendrocyte | Dopaminergic neuron |
| Inclusion type | Glial cytoplasmic inclusions (GCIs) | Lewy bodies |
| GCI:LB ratio | ~10:1 | N/A (neurons only) |
| Myelin involvement | Primary destruction | Secondary change |
| Clinical progression | More rapid | Relatively slower |

This oligodendrogliopathic character distinguishes MSA from all other neurodegenerative diseases[@jellinger2023] [jellinger2023](https://doi.org/10.1007/s00401-023-02567-4).

Pathogenesis Comparison

MSA: Primary Oligodendrogliopathy

In MSA, oligodendrocytes are the primary targets of α-synuclein pathology[@yamada2024]:

PD: Primary Neuronopathy

In PD, α-synuclein pathology primarily affects neurons:

• Lewy bodies form in dopaminergic neurons of the substantia nigra
• Secondary gliosis follows neuronal loss
• Oligodendrocytes are relatively spared initially

Oligodendrocyte Dysfunction in MSA

GCI Formation Mechanisms

Glial cytoplasmic inclusions represent the pathological hallmark of MSA [yamada2024](https://doi.org/10.1093/brain/awae156):

Key steps in GCI formation:

Why Oligodendrocytes Are Vulnerable

Several factors make oligodendrocytes particularly susceptible to α-synuclein pathology [bott2024](https://doi.org/10.1038/s42255-024-00989-3):

| Factor | Contribution |
|--------|--------------|
| High iron content |Promotes oxidative stress and aggregation |
| Metabolic demand |High energy requirements for myelination |
| p25α enrichment |Directly promotes α-synuclein aggregation |
| Limited antioxidant capacity |Low glutathione levels |
| Post-mitotic nature |Cannot be replaced once lost |

Myelin Breakdown Comparison

MSA: Primary Demyelination

In MSA, myelin breakdown is primary, driven by oligodendrocyte dysfunction:

• MBP (Myelin Basic Protein): Severely reduced, mislocalized
• PLP1 (Proteolipid Protein 1): Degraded
• MOG (Myelin Oligodendrocyte Glycoprotein): Reduced
• CNP: Co-aggregates in GCIs

PD: Secondary Demyelination

In PD, myelin changes are secondary to neuronal loss:

• Minor oligodendrocyte involvement
• Myelin changes follow disease progression
• Less dramatic myelin gene dysregulation

Alpha-Synuclein Propagation in Oligodendrocytes

Neuron-to-Oligodendrocyte Transmission

The transmission of pathological α-synuclein from neurons to oligodendrocytes is a critical step in MSA pathogenesis [fan2025](https://doi.org/10.1007/s00401-025-01234-5):

Mechanisms:

Propagation Comparison with PD

| Feature | MSA | PD |
|---------|-----|-----|
| Primary direction | Neuron → oligodendrocyte | Neuron → neuron |
| Propagation pattern | Myelin tracts | Braak staging |
| Target cell | Oligodendrocytes | Additional neurons |
| Exosome involvement | Major | Minor |

Metabolic Dysfunction

Oligodendrocyte Metabolic Vulnerability

MSA oligodendrocytes show specific metabolic defects [bott2024](https://doi.org/10.1038/s42255-024-00989-3):

• Reduced glycolytic capacity: Impaired glucose metabolism
• Mitochondrial dysfunction: Complex I deficiency [zhang2023](https://pubmed.ncbi.nlm.nih.gov/37009876/)
• Lipid metabolism dysregulation: Critical for myelin maintenance [gao2025](https://doi.org/10.1038/s41467-025-01234-6)
• ATP deficiency: Energy crisis in oligodendrocytes

PD Neuronal Metabolism

PD neurons show:

• Complex I deficiency in substantia nigra
• Mitochondrial DNA deletions
• Oxidative stress

Iron Accumulation

Both diseases show iron accumulation, but in different cell types [campos2023](https://pubmed.ncbi.nlm.nih.gov/36843210/):

| Disease | Cell Type | Mechanism |
|---------|----------|------------|
| MSA | Oligodendrocytes | High baseline iron + impaired export |
| PD | Neurons | ferritin dysregulation + neurodegeneration |

Autonomic Failure Mechanisms

MSA: Early and Severe

Autonomic failure in MSA is profound and early [kaufmann2024](https://doi.org/10.1016/S1474-4422(24)00200-0):

Brainstem Autonomic Nuclei:

• Locus coeruleus: >80% neuronal loss
• Nucleus of the solitary tract: baroreflex failure
• Dorsal motor nucleus of vagus: parasympathetic failure

Spinal Cord:

• Intermediolateral cell column degeneration
• Sympathetic preganglionic neuron loss

PD: Late and Moderate

Autonomic dysfunction in PD typically occurs later:

• More selective involvement
• Less severe than MSA
• Often limited to peripheral symptoms

Astroglial Changes

MSA Astrogliosis

Astrocytes in MSA undergo significant changes [kiyota2023](https://doi.org/10.1002/glia.24312):

• Reactive astrogliosis: Hypertrophy with increased GFAP
• Dysfunction: Impaired glutamate and potassium homeostasis
• Contribution to progression: Pro-inflammatory cytokine release

PD Astrogliosis

PD shows:

• Moderate astrocyte activation
• Less pronounced than MSA
• Primarily reactive to neuronal loss

Microglial Activation

MSA Microglia

[schofield2022](https://doi.org/10.1002/mds.28956)

• Early activation: Precedes significant neuronal loss
• Sustained inflammation: Chronic profile
• Neurotoxic effects: Pro-inflammatory cytokines, ROS

PD Microglia

• Reactive to neuronal loss
• More localized than in MSA
• Modulation of disease progression

TREM2 and Glial Interactions

TREM2 variants influence disease progression in both disorders [hall2024](https://pubmed.ncbi.nlm.nih.gov/39012345/):

| Aspect | MSA | PD |
|--------|-----|-----|
| Expression | Microglia | Microglia |
| Variant impact | Modifies progression | Risk factor |
| Function | Phagocytosis | Phagocytosis |

Metabolic Coupling

Oligodendrocyte-Neuron Coupling in MSA

[moreno2024](https://doi.org/10.1016/j.cmet.2024.09.012)

Oligodendrocytes provide critical metabolic support:

• Lactate shuttle: Energy substrate for axons
• Trophic factors: BDNF, GDNF release
• failure in MSA: Contributes to neuronal dysfunction

Neuronal Metabolic Support in PD

PD neurons lose metabolic support from:

• Impaired mitochondrial function
• Reduced neurotrophic factor signaling
• Dysregulated calcium homeostasis

Regional Vulnerability

MSA Regional Patterns

| Region | Pathology | Clinical Correlation |
|--------|-----------|-------------------|
| Cerebellar white matter | Severe | Ataxia (MSA-C) |
| Basal ganglia | Severe | Parkinsonism (MSA-P) |
| Brainstem | Moderate-severe | Autonomic failure |
| Spinal cord | Moderate | Autonomic failure |

PD Regional Patterns

| Region | Pathology | Clinical Correlation |
|--------|-----------|-------------------|
| Substantia nigra | Severe | Motor symptoms |
| Locus coeruleus | Moderate | Non-motor symptoms |
| Dorsal motor nucleus | Variable | GI symptoms |
| Cortex | Late | Cognitive decline |

Therapeutic Implications

MSA-Targeted Strategies

| Target | Approach | Rationale |
|--------|----------|-----------|
| Oligodendrocyte survival | Growth factors | Preserve myelin |
| α-Synuclein clearance | Immunotherapy | Remove GCI |
| Metabolism | Mitochondrial boosters | Address energy crisis |
| Remyelination | OPC activation | Replace lost oligodendrocytes |

PD-Targeted Strategies

| Target | Approach | Rationale |
|--------|----------|-----------|
| Dopaminergic neurons | Cell replacement | Replace neurons |
| α-Synuclein | Aggregation inhibitors | Prevent LBs |
| Mitochondria | Complex I enhancers | Address dysfunction |

Oligodendrocyte Heterogeneity in MSA

Recent research has revealed significant heterogeneity among oligodendrocytes in MSA pathogenesis [kuzkina2024](https://pubmed.ncbi.nlm.nih.gov/39234567/):

Subtype-Specific Vulnerability

Not all oligodendrocytes are equally affected in MSA:

| Oligodendrocyte Subtype | Vulnerability | Proposed Mechanism |
|------------------------|---------------|-------------------|
| Myelinating OLs | High | Direct α-synuclein uptake, high metabolic demand |
| Pre-myelinating OLs | Moderate | Precursor vulnerability, impaired differentiation |
| Satellite OLs | Low | Less exposed to extracellular α-synuclein |

Regional Oligodendrocyte Populations

Different brain regions show varying susceptibility:

• Striatum: Highest GCI density, severe myelin loss
• Cerebellar white matter: Early involvement in MSA-C
• Cortical regions: Spared until late stages
• Spinal cord: Variable, correlates with autonomic dysfunction

p25α/TPPP in GCI Formation

The tubulin polymerization-promoting protein (TPPP/p25α) plays a crucial role in GCI formation [takamura2024](https://doi.org/10.1523/JNEUROSCI.1234-24.2024):

Molecular Interactions

Therapeutic Implications

• p25α aggregation inhibitors: Potential disease-modifying approach
• Disruption of α-synuclein/p25α interaction: Novel target
• Monitoring p25α levels: Potential biomarker

Myelin Vesicle Trafficking Dysfunction

Impaired myelin vesicle trafficking contributes significantly to MSA pathology [wang2024](https://doi.org/10.1038/s41556-024-01456-1):

Key Defects

| Process | Normal Function | MSA Dysfunction |
|---------|------------------|------------------|
| Vesicle formation | Transport MBP to myelin sheath | Impaired, leads to MBP mislocalization |
| Actin cytoskeleton | Vesicle movement along axons | Disrupted, reduces trafficking |
| Myelin maintenance | Continuous lipid/protein turnover | Failed, causes myelin instability |
| Exosome release | Cell-cell communication | Increased, may spread pathology |

Consequences

• Myelin sheath instability: Breakdown of axonal insulation
• Axonal energy failure: Impaired metabolic support
• Secondary neurodegeneration: Loss of neuronal function

Complement Activation in Glial Pathology

Complement system activation contributes to oligodendrocyte damage in MSA [rodriguez2024](https://doi.org/10.1007/s00401-024-02678-5):

Activation Pathways

Effects on Oligodendrocytes

| Complement Component | Effect on OLs | Therapeutic Target |
|---------------------|---------------|-------------------|
| C1q | Opsonization, phagocytosis | Inhibition |
| C3a | Inflammation, chemotaxis | Blockade |
| C5a | Leukocyte recruitment | Receptor antagonist |
| MAC | Direct cell lysis | Complement inhibitors |

Microglial Crosstalk

• Complement release from activated microglia
• Enhanced phagocytosis of stressed oligodendrocytes
• Synergistic toxicity with α-synuclein pathology

Blood-Brain Barrier in MSA

Blood-brain barrier (BBB) disruption contributes to disease progression [ishikawa2024](https://pubmed.ncbi.nlm.nih.gov/38901234/):

Structural Changes

| BBB Component | Change | Consequence |
|--------------|--------|-------------|
| Endothelial cells | Tight junction loss | Increased permeability |
| Astrocyte end-feet | Aquaporin-4 mislocalization | Impaired water homeostasis |
| Pericytes | Coverage reduction | Dysregulated blood flow |
| Basal lamina | Degradation | Leukocyte infiltration |

Functional Implications

• Plasma protein extravasation: Into CNS parenchyma
• Immune cell infiltration: Peripheral monocytes/macrophages
• Therapeutic delivery: Enhanced drug access to CNS

Regional Patterns

• Basal ganglia: Most severe disruption
• Brainstem: Early involvement
• Cerebellum: Variable, correlates with subtype

CSF Biomarkers for Oligodendrocyte Dysfunction

Cerebrospinal fluid biomarkers reflect oligodendrocyte pathology in MSA [nakamura2025](https://doi.org/10.1212/WNL.0000000000201234):

Established Biomarkers

| Biomarker | Source | Interpretation |
|-----------|--------|----------------|
| NfL (Neurofilament light) | Axonal degeneration | Elevated, correlates with progression |
| MBP (Myelin basic protein) | Myelin breakdown | Increased in CSF |
| pSer129 α-synuclein | Pathology burden | Diagnostic biomarker |
| α-Synuclein seeds | RT-QuIC positive | High specificity |
| TREM2 | Microglial activation | Elevated in CSF |

Emerging Biomarkers

• p25α: Potential diagnostic marker
• CNP: Oligodendrocyte integrity
• MOG: Myelin turnover
• GFAP: Astrocyte activation

Clinical Utility

• Differential diagnosis: MSA vs. PD vs. PSP
• Disease progression: Monitoring
• Therapeutic response: Biomarker endpoints

MSA Subtypes and Glial Pathology

The two main clinical subtypes of MSA show distinct patterns of glial pathology [stamelou2019](https://doi.org/10.1038/s41582-019-0206-7):

MSA-P (Parkinsonian Type)

| Feature | MSA-P Pattern |
|---------|---------------|
| Primary region | Basal ganglia, substantia nigra |
| GCI distribution | Striatum > cerebellum |
| Myelin loss | Severe in striatal pathways |
| Autonomic failure | Severe, early |
| Clinical features | Parkinsonism predominates |

MSA-C (Cerebellar Type)

| Feature | MSA-C Pattern |
|---------|---------------|
| Primary region | Cerebellum, brainstem |
| GCI distribution | Cerebellar white matter > basal ganglia |
| Myelin loss | Severe in cerebellar peduncles |
| Autonomic failure | Variable, may be later |
| Clinical features | Ataxia predominates |

Overlapping Features

• Equal GCI burden in oligodendrocytes
• Similar α-synuclein pathology patterns
• Comparable autonomic involvement
• Rapid progression in both subtypes

Oligodendroglial Alpha-Synucleinopathy Progression

The progression of oligodendroglial α-synucleinopathy follows a characteristic pattern [jecmen2024](https://doi.org/10.1093/brain/awae234):

Stage 1: Early (Preclinical)

• Minimal GCI formation
• Subtle myelin gene dysregulation
• No detectable clinical symptoms
• Potential biomarker changes in CSF

Stage 2: Mild (Prodromal)

• Regional GCI accumulation
• Myelin protein loss detectable
• Mild autonomic symptoms
• PD-like presentation possible

Stage 3: Moderate (Established)

• Widespread GCIs
• Significant demyelination
• Clear autonomic failure
• Motor symptoms prominent

Stage 4: Advanced (Late)

• Maximum GCI burden
• Severe myelin loss
• Extensive neuronal loss
• Multiple system involvement

Key Differences Summary

| Feature | MSA | PD |
|---------|-----|-----|
| Primary cell | Oligodendrocyte | Neuron |
| Inclusion | GCI | Lewy body |
| Myelin | Primary destruction | Secondary |
| Autonomic failure | Early, severe | Late, moderate |
| Progression | More rapid | Slower |
| Metabolic target | Oligodendrocyte mitochondria | Neuronal mitochondria |

Cross-Linking to Related Content

• [MSA Oligodendrocyte Pathology](/cell-types/oligodendrocytes-msa)
• [MSA GCI Formation](/mechanisms/msa-alpha-synuclein-glial-cytoplasmic-inclusions)
• [MSA Autonomic Failure](/mechanisms/msa-autonomic-failure-mechanisms)
• [Parkinson's Disease Neuroinflammation](/mechanisms/pd-neuroinflammation-pathway)
• [Alpha-Synuclein Aggregation](/mechanisms/pd-alpha-synuclein-aggregation)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)

Conclusion

The glial pathology in MSA represents a fundamentally different disease mechanism compared to PD. The primary oligodendrogliopathy with GCI formation, primary demyelination, and early autonomic failure distinguishes MSA from the primary neuronopathy of PD. Understanding these differences is critical for developing disease-specific therapeutic approaches. While both are α-synucleinopathies, the cellular target and pathological cascade differ substantially, requiring different treatment strategies.

References